Besser GM, Cudworth AG, eds. Clinical endocrinology: an illustrated text. London: Gower Medical Publishing, 1987
önksen PH et al. In: Adashi EY, Thorner MO, eds. The somatotrophic axis of the reproductive process in health and disease. New
York: Springer-Verlag, 1995
Sönksen PH et al. In: Adashi EY, Thorner MO, eds. The somatotrophic axis of the reproductive process in health and disease. New
York: Springer-Verlag, 1995
• Increased fat mass
• Reduced lean body mass
• Decreased extracellular water (dry, thin skin)
• Low bone density
• Impaired cardiac function
• Poor physical performance
• Impaired psychological well-being
Increased abdominal adiposity
Symptoms
Decreased psychological well-being
Reduced strength and physical endurance
Thin, dry skin
Signs
Truncal obesity
Increased waist:hip ratio
Thin, dry skin
Abnormal body composition
Decreased psychological well-being
Reduced exercise performance
Abnormal cardiac structure and function
Cardiovascular risk factors
Disturbed renal function
Lowered basal metabolic rate
Increased insulin
resistance
Modified from Cuneo et al. Clin Endocrinol 1992; 37: 387-97
Ho KY, Hoffman DM. In: Laron Z, Butenandt O, eds. Growth hormone replacement therapy in adults – pros and cons.
Tel Aviv/London: Freund Publishing House, 1993: 5-1
6
Mårdh G et al. Endocrinol Metab 1994; 1 (Suppl A): 43-9
Russell-Jones DL et al. Acta Endocrinol 1993; 128 (Suppl 2): 44-7
Johannsson G et al. Endocrinol Metab 1996: 3 (Suppl A): 3-12
With kind permission of Professor B Angelin
0 months 12 months 24 months
Cholesterol P 234 (59) 233 (48) 232 (44)
(mg/dL) V 269 (56) 231 (60)*** 226 (50)***
LDL Cholesterol P 167 (56) 168 (49) 159 (45)
(mg/dL) V 191 (51) 160 (59)** 151 (52)***
TC/HDL-C P 5.9 (1.9) 5.8 (1.5) 5.3 (2.2)
V 7.6 (3.3) 5.6 (2.0)** 5.4 (1.7)**
LDL-C/HDL-C P 4.3 (1.7) 4.1 (1.4) 3.7 (2.0)
V 5.2 (2.1) 3.9 (1.8)** 3.6 (1.5)**
Lp (a) P 9.5 8.4 11.8++
(0.4 – 44.8) (0.6 – 54.0) (1.2 – 89.1)
V 6.7 9.0 10.6
(0.5 – 87.4) (0.7 – 181.0) (1.05 – 162.0)
Table 2, Nolte, p 137.
Rosèn and Bengtsson. Lancet 1990; 336: 285-8; 77: 1671-6
Bülow B et al. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients.
J Clin Endocrinol Metab. 1997; 46: 75-81.
Cerebrovascular Disease
Bülow B et al. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients.
J Clin Endocrinol Metab. 1997; 46: 75-81.
Amato et al. J Clin Endocrinol Metab 1993; 77: 1671-6
Colao A et al. JCEM 84:1919, 1999
Fig. 1. Lumbar spine BMD (right panel) and femoral neck BMD (left panel) evaluated as t scores in the five groups of subjects
divided on the basis of the GH response to ARG+GHRH test: very severe GHD, GH peak below 3 µg/L; severe GHD, GH peak
between 3. 1-9 µg/L; partial GHD, peak between 9.1-16.5 ug/L; non-GHD, GH peak above 16.5 µg/L; and controls, GH peak
above 16.5 µg/L. *, P < .001, group 1 vs. groups 3-5. **, P < .05, group 2 vs. groups 1 and 5.
Rosèn et al, Eur J Endocrinol 1997
Vandeweghe M et al. Clin Endocrinol (Oxf) 1993; 39: 409-15
Mårdh G et al. Endocrinol Metab 1994; 1 (Suppl A): 43-9
• NHP revealed improvements in overall score
• Improved energy levels and emotional score
in GH treated 10-year group vs. untreated
Gibney J et al. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients.
J Clin Endocrinol Metab. 1999; 84: 2596-2602.
Fig. 1. Mean (
±SE) measured
(•) and expected ( ) changes
in body composition
parameters from baseline
values in men with GHD
receiving GH for 5 yr. Data are
shown for body weight, leg
muscle area (measured by
computed tomographic
scanning), sum of skinfolds
(measured at seven sites with
a Harpenden skinfold caliper),
and intraabdominal fat
(measured by computed
tomographic scanning). n = 38
unless stated otherwise. *,
P < .001 for comparison of
changes from baseline.
Ter Maaten et al.
Fig. 2. Mean (
±SE) changes in
BMD/bone mineral content
from baseline values in men
with GHD receiving GH for
5 yr. Data are shown for BMD
of the spine, femoral neck, and
trochanter and for total bone
mineral content (measured
by dual energy x-ray
absorptiometry).
n = 38 unless stated
otherwise. *,
P < .05; †,
P < .01;
‡,
P < .001 (for comparison of
changes from baseline).